Trial
NCT03044249
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Mediti Pharma Inc.
Collaborators
—
Condition
Psychosis
Intervention
MP-101
Why stopped
Statistical futility; totality of evidence suggests study unlikely to meet endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-01